OPR - Delayed Quote • USD KROS Sep 2024 70.000 call (KROS240920C00070000) Follow 11.20 0.00 (0.00%) As of March 15 at 2:02 PM EDT. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for KROS240920C00070000 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: KROS Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%? Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference Keros Therapeutics Inc (KROS) Reports Increased R&D Spending and Net Loss in 2023 Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect? Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress Keros Therapeutics, Inc. (NASDAQ:KROS) institutional owners may be pleased with recent gains after 2.4% loss over the past year Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
